Rectal retractor application during image-guided dose-escalated prostate radiotherapy.

Abstract

To investigate efficacy of arectal retractor (RR) on rectal dose during image-guided dose-escalated prostate three-dimensional conformal radiotherapy (3DCRT). In all, 21patients with localized prostate cancer were treated with aRR for 3DCRT in 40 × 2 Gy. Patient underwent two scans for radiotherapy planning, without and with RR. RR was used for the first half of the treatment sessions. Two plans were created for each patient to compare the effect of RR on rectal doses. PTW-31014 Pinpoint chamber embedded within RR was used for in vivo dosimetry in 6of 21patients. The patient tolerance and acute rectal toxicity were surveyed during radiotherapy using Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. Patients tolerated the RR well during 20fractions with mild degree of anal irritation. Using aRR significantly reduced the rectal wall (RW), anterior RW and posterior RW dose-volume parameters. The average RW Dmean was 29.4 and 43.0 Gy for plans with and without RR, respectively. The mean discrepancy between the measured dose and planned dose was -3.8% (±4.9%). Grade1 diarrhea, rectal urgency and proctitis occurred in 4, 2 and 3 cases, respectively. There were no grade ≥2 acute rectal toxicities during the treatment. Rectal retraction resulted in asignificant reduction of rectal doses with asafe toxicity profile, which may reduce rectal toxicity. Dosimeter inserted into the RR providing apractical method for in vivo dosimetric verification. Further prospective clinical studies will be necessary to demonstrate the clinical advantage of RR.